Metabolic abnormalities and liver stiffness evaluated by Transient Elastography in HIV and HIV/HCV coinfected patients by Catarina Magalhães Castelo Branco
2013/2014 
Catarina Magalhães Castelo Branco 
 
Metabolic  abnormalities  and liver stiffness evaluated by 
Transient  Elastography in HIV and HIV/HCV coinfected patients 
março, 2014 
Mestrado Integrado em Medicina 
 
Área: Endocrinologia 
 
Trabalho efetuado sob a Orientação de: 
Doutora Paula Isabel Marques Simões de Freitas 
 
 
Trabalho organizado de acordo com as normas da revista: 
BMC Infectious Diseases 
Catarina Magalhães Castelo Branco   
Metabolic abnormalities and liver stiffness evaluated by  
Transient Elastography in HIV and HIV/HCV coinfected patients 
Março, 2014 


- 1 - 
 
Metabolic abnormalities and liver stiffness evaluated by 
Transient Elastography in HIV and HIV/HCV coinfected 
patients 
 
Catarina Castelo-Branco
1§, Eva Lau
1,2
, Joana Oliveira
1,2
, Ana Cristina Santos
1,3
, Rosário 
Serrão
4
, Luís Ferreira-Pinto
1
, António Sarmento
1,4
, Davide Carvalho
1,2
, Paula Freitas
1,2 
 
1
University of Porto Medical School 
2
Department of Endocrinology, Diabetes and Metabolism of Centro Hospitalar São João, E.P.E. 
3
Department of Clinical Epidemiology, Predictive Medicine and Public Health , University of 
Porto Medical School, and University of Porto Institute of Public Health, Porto, Portugal  
4 
Infectious Diseases Department of Centro Hospitalar de São João, E.P.E. 
 
§
Corresponding author 
 
 
Email addresses: 
CCB: catarinamcbranco@gmail.com 
  
- 2 - 
 
Abstract  
Background 
Hepatitis C Virus (HCV) infection is highly prevalent among HIV infected patients. 
Liver disease and metabolic complications are the major concerns about their 
management and the main causes of morbimortality. It is still not fully understood how 
the presence of coinfection affects the metabolic profile and the natural history of the 
liver disease. 
Methods 
Retrospective cohort study including 299 adults under combined antiretroviral therapy 
(cART) (236 HIV monoinfected and 63 HIV/HCV coinfected patients). Insulin 
Resistance (IR) was defined as HOMA-IR≥2. Coinfected patients were divided into 4 
groups according to the presence of fibrosis defined by Liver Stiffness (LS): 1) absence 
of significant fibrosis, if LS≤6.0 kPa; 2) undetermined fibrosis, if 6.0<LS<9.0 kPa; 3) 
significant fibrosis, if 9.0≤LS<14.6 kPa; 4) cirrhosis, if LS≥14.6 kPa.  
Results 
HIV/HCV coinfected patients presented lower body mass index, waist circumference, 
hypertension and lipid levels in comparison to HIV mono-infected patients. Glucose 
metabolism parameters did not differ according to HCV serostatus and IR was found in 
approximately half of the patients in both groups. 
In HIV/HCV coinfected patients, fibrosis grade was associated with differences in non-
nucleoside reverse transcriptase inhibitors (NNRTI) use, duration of HCV infection and 
HCV genotype. Regarding metabolic characteristics, higher glutamic oxaloacetic 
transaminase (GOT) levels and lower total cholesterol (TC), non-high density 
lipoprotein cholesterol (Non-HDL-C) and albumin were observed in the presence of 
liver fibrosis.  
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NNRTI, TC, GOT(ln), albumin, glucose(ln) and age were included in the linear 
regression for LS. TC [β=-0.038 (-0.074;-0.001)] and albumin [β=-0.896 (-1.191;-
0.602)] were found to be inversely associated with LS. 
Conclusions 
HIV/HCV coinfection was associated with better metabolic profile than HIV 
monoinfection, except for insulin resistance that was similar in both groups. Total 
cholesterol and albumin were independently and inversely associated with liver 
stiffness. 
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Background  
Hepatitis C Virus infection has an extremely high prevalence among Human 
Immunodeficiency Virus (HIV) infected patients, affecting 4 to 5 million people 
worldwide [1]. In the setting of HIV/HCV coinfection, rapid rates of fibrosis 
progression were observed [2] and end-stage liver disease is now the primary cause of 
death among patients under cART [3].  
HIV/HCV coinfection pathogenesis is still not fully understood. Both HIV and 
HCV infections give rise to glucose and lipid disorders, bringing up to discussion how 
the presence of coinfection influences the metabolic status. Metabolic changes in 
HIV/HCV coinfected patients have been associated with accelerated progression of liver 
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disease, lower rates of response to anti-HCV therapy as well as cardio and 
cerebrovascular complications [4, 5]. 
As a result, the development of measures that may slow down the progression of 
HCV related liver disease should be a priority [3]. Earlier recognition of these metabolic 
changes may be an important step to allow an improved therapeutic approach, both to 
the viral infection and to the metabolic diseases [6]. 
Staging and monitoring liver fibrosis is a key concern in the management of 
coinfected patient, which requires a tool that is reliable, relatively inexpensive and 
accurate. Transient Elastography (TE) is a non-invasive test to assess liver fibrosis by 
measuring liver stiffness, validated to predict significant fibrosis and cirrhosis in 
HIV/HCV coinfected patients. Besides avoiding the complications inherent to liver 
biopsy, it also outgrows the latter in terms of sampling errors, inter-observer variability 
and acceptance by the patients [7, 8]. 
The aim of this study was to evaluate the prevalence of clinical and metabolic 
parameters, comparing HIV monoinfected with HIV/HCV coinfected patients and to 
identify the factors associated with significant liver fibrosis, assessed by TE in 
HIV/HCV coinfected patients. 
 
Methods 
Subjects 
As part of a cross-sectional study, 299 non-institutionalized HIV infected 
Caucasian adults under cART followed in the Infectious Diseases and Endocrinology 
Out-patient Clinic of Centro Hospitalar de São João were included: 236 HIV 
monoinfected and 63 HIV/HCV coinfected patients. Only the coinfected patients who 
had a TE evaluation from 2013 were included.  Patients with a previous diagnosis of 
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diabetes or hepatitis B were excluded. The study protocol was approved by the Hospital 
Ethics Committee and all patients provided informed consent.  
Clinical assessment 
For each patient, the following information was collected using a standardized 
protocol: demographic data (age, gender), duration of HIV and HCV infection, duration 
of cART, history of hypertension, use of antihypertensive or lipid lowering drugs and 
alcohol use. Weight, height, waist circumference and resting blood pressure were 
measured as previously described [9]. 
A venous blood sample was drawn after a 12-hour overnight fast. All the 
samples were analyzed at the central laboratory of our hospital. Plasma glucose, insulin, 
GOT, glutamic pyruvic transaminase (GPT), gamma-glutamyl transpeptidase (GGT), 
alkaline phosphatase (ALP), albumin, platelets, total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-C) and triglycerides (TGL) were determined using 
automatic standard routine enzymatic methods. The CD4+ cell count was determined by 
flow cytometry and plasma RNA-HIV and RNA-HCV were measured by a quantitative 
reverse transcriptase polymerase chain reaction (PCR), which had a lower limit of 
detection of 50 copies/mL. HCV infection was diagnosed by the presence of serum 
antibodies against HCV (RIBA test) and detectable serum HCV RNA PCR.  
Insulin resistance 
Insulin resistance was defined by the homeostasis model assessment of insulin 
resistance (HOMA-IR) and insulin sensitivity by the quantitative insulin sensitivity 
check index (QUICKI). These indexes were calculated by the following formulas: 
HOMA-IR index = (fasting plasma insulin [mU/L] x fasting plasma glucose [mg/dL])/450 
[10]. QUICKI = 1/[log (fasting insulin [mU/L]) +log (fasting plasma glucose [mg/dL]) 
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[11]. A threshold of HOMA-IR≥2 was considered as the clinical definition of 
significant IR in our study [12, 13]. 
Liver fibrosis 
Liver fibrosis was determined by Transient Elastography (Fibroscan®, 
Echosens, Madrid), according to the standardized technique, by a trained physician, and 
results were expressed as the median value of acquisitions in kilopascals (kPa). At least 
10 valid measurements were obtained for each patient. To guarantee the validity of TE 
results, we considered for analysis only the examination with an interquartile range 
(IQR) below 30% of the median value and a success rate of acquisitions above 60% 
[14]. 
LS ≥ 9.0 kPa for the presence of significant liver fibrosis shows a positive 
predictive value of 87% for Metavir fibrosis index F≥2. To discard F of 2 and above, a 
cut-off of 6.0 kPa shows a negative predictive value of 90% [15]. LS higher than 14.6 
kPa for the presence of liver cirrhosis shows positive and negative predictive values of 
86% and 94%, respectively [16]. According to these values, four groups were defined: 
1) without significant fibrosis, if LS≤6.0 kPa; 2) undetermined fibrosis, if 6.0<LS<9.0 
kPa; 3) significant fibrosis, if 9.0≤LS<14.6 kPa; 4) cirrhosis, if LS≥14.6 kPa.  
Statistical analysis 
Data were presented as mean and standard deviation (SD) for quantitative 
variables when normally distributed or as median and respective 25
th
 and 75
th
 
percentiles when the variable distribution was different than the normal. For comparison 
between quantitative variables Student-t test and the Mann-Whitney test were used 
when appropriate. Categorical variables were described as counts and proportions, and 
compared using the chi-square or Fisher’s exact test. Pearson’s correlation and 
Spearman’s non-parametric rank correlation were used to assess the association between 
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LS and metabolic parameters, according to the variable distribution In order to assess 
the independent associations between the established metabolic and clinical 
characteristics and LS, multivariable linear regression models were computed and β 
coefficients and respective 95% confidence intervals (95% CI) were estimated. 
Statistical analysis was performed using the SPSS version 21.0 software (SPSS 
Inc., Chicago, Illinois, USA). All probabilities were two tailed and p values < 0.05 were 
regarded as significant. 
 
Results  
A total of 299 patients under cART were included in the study, 236 with HIV 
monoinfection and 63 with HIV/HCV coinfection. The main characteristics of HIV and 
HIV/HCV infected patients are summarized in Table 1. Coinfected patients were more 
often males. Age was similar in both groups. Coinfected patients presented longer HIV 
infection and cART cumulative exposure, as well as lower CD4 cell count. Suppressed 
HIV RNA replication was similar in both groups. In terms of cART regimen, HIV 
monoinfected patients had higher use of nucleoside reverse transcriptase inhibitors 
(NRTI) but the use of protease inhibitors (PI) or non-nucleoside reverse transcriptase 
inhibitors (NNRTI) was not statistically different between groups. The groups did not 
differ in terms of reported alcohol use. 
Among the coinfected group, genotype 1 VHC infection was the most common 
(69.8%), mean duration of HCV infection was 10.6 ±5.1 years and median HCV RNA 
load was 6.04 (5.38-6.61) log10 
3
. 
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Metabolic profile according to HCV serostatus 
Metabolic profile in HIV and HIV/HCV coinfected groups is described in 
Table 2. 
HIV monoinfected patients had higher body mass index (BMI), waist 
circumference and more prevalence of hypertension and antihypertensive medication 
use. 
A more aterogenic lipid profile was also found in this group: higher levels of 
total cholesterol, low density lipoprotein cholesterol (LDL-C), Non-HDL-C and 
triglycerides (TGL), as well as greater use of antidyslipidemic therapy. No differences 
were found in high density lipoprotein cholesterol (HDL-C). 
Hepatic profile was less favourable in HIV/HCV coinfected patients, 
characterized by higher serum levels of GOT, GPT, GGT and ALP. Both albumin and 
platelet count were lower in this group. 
No differences were found between the groups in glucose metabolism 
parameters except for fasting glucose that was higher in the HIV monoinfected patients. 
IR was present in 44.5% and 50.8% of HIV monoinfected and HIV/HCV coinfected 
patients, respectively. 
 
Absence vs Presence of Significant Liver Fibrosis 
The main characteristics of HIV/HCV infected patients according to liver 
fibrosis stage are summarized in Table 3. 
None of the epidemiologic HIV related characteristics were significantly 
different between groups of liver fibrosis. Fibrosis grade was associated with 
differences in NNRTI use and HCV genotype but no differences were found for other 
HCV related characteristics. 
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Metabolic profile according to Liver Fibrosis Stage 
None of the clinic, lipid, hepatic and insulin resistance parameters mentioned 
above varied in the presence of significant liver fibrosis, with exception of GOT, TC, 
Non-HDL-C and albumin. LDL-C was marginally different between groups. No 
differences were found between the groups in terms of the glucose metabolism 
parameters (Table 4). TC, LDL-C, Non-HDL-C, glucose and albumin were negatively 
correlated with LS (Table 5).  
 
Association between clinical and metabolic characteristics and Liver Stiffness  
All factors previously significantly associated with LS in HIV/HCV coinfected 
patients, namely NNRTI, TC, GOT(ln), albumin and glucose(ln) were included in the 
model. Age was also included as a potential confounder. Among those, TC [β=-0.038 
(95%CI: -0.074;-0.001)] and albumin [β=-0.896 (95%CI: -1.191;-0.602)] were 
inversely associated with LS (Table 6). 
 
Discussion  
Metabolic profile 
HIV infected and cART exposed individuals are at increased risk for 
hyperglycaemia, insulin resistance and type 2 diabetes mellitus (T2DM), given to direct 
HIV effect on the pancreas, cART associated lipodystrophy, PI’s effects on GLUT4 and 
NRTI induced mitochondrial toxicity [17, 18]. 
Glucose metabolism disturbances, ranging from IR to overt Diabetes Mellitus 
(DM), are also a common comorbid condition in those with HIV/HCV coinfection [19].  
Nevertheless, HCV infection relevance as risk factor for T2DM is somewhat less clear 
in this group [20]. Previous studies found an association between HCV infection and 
- 10 - 
 
risk of incident diabetes in HIV patients under cART, but failed to find it when 
controlled for traditional risk factors and cART exposure [17, 21], strengthening the 
hypothesis of HCV having a permissive rather than a direct effect on the development 
of diabetes. On the contrary, Jain et al described that HCV related DM may have a 
different phenotype, as individuals who were young, lean and had no family history 
were twice as likely to have DM [19]. HCV is thought to have a direct role in IR 
development through changes in insulin signalling, glucose entry into the cell and 
reduced expression of PPARα, and an indirect role due to hypersecretion of 
proinflammatory cytokines and endoplasmic reticulum stress [17, 22]. On the other 
hand, given that liver and endocrine disorders have a bidirectional relationship, more 
severe liver disease may also play a part in the pathogenesis of IR [19, 22]. IR was 
present in more than a half of HIV/HCV coinfected cohort, with 50.8% having a 
HOMA-IR≥2 and 17.5% having very high levels of insulin resistance (HOMA-IR≥4). 
Similar values of HOMA-IR, QUICKI and fasting insulin were found between 
groups though coinfected patients presented lower BMI and waist circumference and 
less frequent use of NRTI combinations, previously described as confounders in this 
setting [17, 20, 21]. Anthropometric parameters, preponderant risk factors for IR in the 
general population, might explain why HIV monoinfected patients had higher fasting 
glucose in this cohort. Conversely, coinfected patients were more often males and had 
longer exposure to cART, which are also recognized as independent factors for IR 
development [18, 20]. Other aggravating determinants, such as older age and PIs use, 
did not differ significantly between groups [18, 20]. 
In HIV infected patients receiving cART, there is a high but variable prevalence 
of hyperlipidemia across the studies, which we also found in this cohort: increased TC, 
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LDL-C and TGL, and decreased HDL-C, given to HIV infection itself, low grade 
inflammation, lipodystrophy and antiretroviral molecules [18].  
There is growing evidence that HIV/HCV coinfection has a direct effect on lipid 
profiles and lipoprotein concentrations as the virus life cycle relies on hepatic lipid 
metabolism for HCV assembly and maturation [4, 6]. These changes have been 
described to be more pronounced in patients with HCV genotype 3 and higher HCV 
viraemia and seem to be present despite cART [4] and absence of advanced liver 
disease [23]. In our study, coinfected patients presented lower levels of TC, LDL-C, 
non-HDL-C and TGL and less frequent use of lipid-lowering drugs, which is in 
accordance to what was previously described [4, 6, 23]. 
GOT, GPT, GGT and ALP levels were higher in the coinfected group, which 
probably reflects the greater extension of the hepatic lesion and cholestasis as a 
consequence of more advanced fibrosis. 
In summary, HIV monoinfected patients had a metabolic profile which fits 
metabolic syndrome’s features whereas those with coinfection had lower prevalence of 
the traditional risk factors. It is known, however, that both infections are associated with 
higher risk of cardiovascular disease. Therefore, viral hepatitis status should be taken 
into account when evaluating cardiovascular disease risk in HIV infected patients. 
 
Liver disease progression 
Successive studies have demonstrated that HIV coinfection accelerates 
progression of hepatic fibrosis in HCV infected patients [24-26]. Various pathways 
have been implicated including: direct viral effects, immune dysregulation, profibrotic 
cytokine environment, depletion of gut CD4 cells and microbial translocation, oxidative 
stress and hepatocyte apoptosis [1, 27]. Moreover, the chronic viral state and the host 
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immune response both in HIV and HCV infections give rise to glucose and lipid 
metabolic disorders that, in turn, are risk factors for liver damage [1, 28]. cART benefits 
in reducing liver disease progression by improving host immunity seem to outweigh its 
hepatotoxicity and IR risk [3, 29, 30]. 
In HCV infection, low lipid levels have been correlated not only with steatosis 
and more advanced liver fibrosis, but also with non-response to interferon treatment [4]. 
This is in line with what was observed in this study: those with higher grades of fibrosis 
had lower TC and non-HDL-C. TC remained significantly inversely associated with LS, 
independently of age, NNRTI, TC, GOT and albumin. 
GOT elevations are common with fibrosis progression but they are not a good 
marker, especially in those with HIV infection, in whom the use of cART also 
contributes to alterations in the hepatic profile.  Normal level of GOT should not 
exclude the need of anti-HCV treatment because there are patients who develop fibrosis 
in the absence of transaminases elevation [25]. Lower albumin is an established marker 
of hepatic insufficiency. In our cohort, albumin levels were negatively associated with 
LS in our model for liver fibrosis, independently of the other variables included in the 
multivariated model. 
Current literature is not yet accordant regarding IR importance to the 
pathogenesis of accelerated fibrosis progression in HIV/HCV infected individuals, as 
some studies described a positive correlation between IR and more advanced grades of 
fibrosis [12, 31, 32] and others did not find that association [13, 33]. Moreover, it was 
reported that IR is associated with a poor sustained virological response to HCV 
treatment in HIV/HCV coinfected as well as in HCV monoinfected patients [34, 35]. 
On the other hand, this relationship has been consistently reported for HCV 
monoinfection, suggesting that IR is a determinant of fibrogenesis in chronic hepatitis 
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C, independent of hepatic steatosis, through direct stimulation of hepatic stellate cells 
by hyperglycaemia and hyperinsulinemia to proliferate and to secrete extracellular 
matrix [36-39]. Concomitantly, IR promotes hepatic lipogenesis and it is plausible that 
steatosis per se contributes to fibrogenesis.  
No association was found for glucose (ln) and LS in the multivariated model, 
similarly to what has been described by Halfon and Mechante [13, 33]. Besides the 
small size of our cohort that may have been responsible for the lack of association 
found, other factors may play a more relevant role in fibrogenesis than IR in the setting 
of HIV/HCV coinfection comparing to those with HCV monoinfection.  
Low CD4+ cell count and history of AIDS, older age and greater length of HCV 
infection, HCV genotype 3, alcohol consumption, elevated GPT levels and greater waist 
circumference [7, 24-26] have been previously associated with increased liver fibrosis 
in a HIV/HCV coinfection context. Among these, only length of HCV infection was 
different across fibrosis stage groups.  
Known risk factors for accelerate fibrosis progression are still unable to explain 
the wide spectrum of evolution of liver disease in HIV/HCV coinfection. Thus, further 
studies are required to identify other factors potentially associated with liver fibrosis in 
this setting. 
The main limitation of our study was the small size of the population. We were 
unable to distinguish the temporal relationship given the cross-sectional nature of the 
study. Alcohol use was self reported and not quantified. Lack of data on other potential 
confounders, such as lipodystrophy, family history of diabetes mellitus could also affect 
the interpretation of our findings. Finally, the cohort may not be representative of the 
HIV/HCV coinfected population since the decision to undergo a TE evaluation was 
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made by the caring physician and only the ones who accepted to do an IR screening 
were included. 
 
Conclusions  
In this cohort, HIV/HCV infection was associated with better metabolic profile 
than HIV monoinfection, except for IR that was similar in both groups. 
In HIV/HCV coinfected patients, fibrosis grade was associated with differences 
in NNRTI use, duration of HCV infection and HCV genotype. Patients with liver 
fibrosis had higher GOT levels and lower TC, Non-HDL-C and albumin. TC and 
albumin were independently and inversely associated with LS value. 
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Tables 
Table 1  - Sample descriptive statistics and comparison between monoinfected 
HIV patients and coinfected HIV/HCV patients. 
 
HIV 
(n = 236) 
HIV/HCV 
(n = 63) 
p 
Gender 1    <0.001 
 
Female 95 (40.3) 7 (11.1) 
 
 
Male 141 (59.7) 56 (88.9) 
Age  years 2 44 (11.48) 43 (6.54) 0.074 
Duration of HIV infection  years  3  8 (5-10) 13 (9-17) <0.001 
CD4 cell count 3 504 (338-716) 366 (285-566) 0.001 
<50 HIV RNA copies/mL 1 211 (89.4) 56 (88.9) 0.906 
cART cumulative exposure  years  
3 
6 (3-10) 9 (5-12) <0.001 
ART 1    
 
PI  136 (57.6) 41 (65.1) 0.285 
 
NNRTI 110 (46.6) 21 (33.3) 0.059 
 
NRTI 232 (98.3) 57 (90.5) 0.007 
G 
   
Duration of HCV infection  years  2  10.6 (5.05) 
 
HCV RNA log10 
3  
6.04 (5.38-
6.61)  
Genotype 1  
  
       1  44 (69.8) 
 
       3  13 (20.6) 
 
       4  6 (9.5) 
 
    
Alcohol consumption 1 85 (36.0) 27 (42.9) 0.319 
1 – number (%); 2 – mean (SD); 3 – median (IQR) 
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Table 2  - Clinical and metabolic features and comparison between monoinfected 
HIV patients and coinfected HIV/HCV patients. 
 
 HIV HIV/HCV  p 
   hjvh 
BMI kg/m2 1 25.2 (4.3) 22.9 (2.9) <0.001 
Waist circumference  cm 1  91.6 (11.3) 85.3 (8.4) <0.001 
    
High blood pressure2  82 (34.7) 5 (7.9) <0.001 
Antihypertensive medication2  31 (13.1) 1 (1.6) 0.008 
    
Total cholesterol mg/dL 1 227.5 (56.4) 167.3 (35.8) <0.001 
LDL cholesterol  mg/dL 1 136.4 (48.5) 97.5 (25.0) <0.001 
HDL cholesterol  mg/dL 1 47.2 (13.8) 46.5 (15.1) 0.717 
Non-HDL Cholesterol  mg/dL 3 180.0 (142.0-214.0) 127.0 (104.0-139.0) <0.001 
Triglycerides  mg/dL 1 266.0 (193.5) 146.3 (71.8) <0.001 
Antidyslipidemic therapy 1 114 (48.3) 9 (14.3) <0.001 
    
GOT U/L 3 24.0 (19.3-32.8) 41.0 (29.0-68.0) <0.001 
GPT  U/L 3 24.0 (18.0-37.0) 56.0 (36.0-95.0) <0.001 
GGT  U/L 3 40.0 (26.0-76.5) 95.0 (46.0-165.0) <0.001 
ALP   U/L 3 82.50 (64.0-105.0) 93.0 (76.0-115.0) 0.008 
Total bilirubin  U/L 3 0.98 (0.96) 0.93 (0.59) 0.068 
Albumin g/L 1 44.1 (3.3) 43.0 (4.4) <0.001 
Platelets x109/L 1 215.9 (58.1) 172.4 (65.9) 0.039 
Prothrombin time  mg/dL 1 --- 12.3 (1.4)  
Fibrinogen  mg/dL 1 --- 335.2 (92.1)  
Liver stiffness kPa 3 --- 7.1  (5.4-9.8)  
    
HOMA-IR 3 1.8 (1.2-3.1) 2.0 (1.0-3.3) 0.855 
HOMA-IR ≥ 2 2 105 (44.5) 32 (50.8) 0.372 
HOMA-IR ≧4 2 37 (15.7) 11 (17.5) 0.732 
QUICKI 3 0.35 (0.32-0.37) 0.34 (0.32-0.38) 0.855 
Glucose mg/dL 3 90.5 (83.0-98.8) 84.0 (78.0-95.0) 0.001 
Insulin  mU/L 3 8.1 (5.3-13.1) 9.6 (5.1-14.6) 0.347 
HbA1C % 1 5.3 (0.49) 5.1 (0.63) 0.055 
1 – mean (SD); 2 – number (%); 3 – median (min, max | IQR) 
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Table 3  - Main features of the HIV/HCV coinfected patients according to liver 
fibrosis stage. 
 
 
 
 
  
 
 
 
Without 
Significant 
Fibrosis 
Undetermined 
Fibrosis 
Significant 
Fibrosis 
Cirrhosis p 
 (n=22) (n=21) (n=14) (n=6)  
 
Jhh 
    
Gender 1  
    
0.700 
Female 4 (18.2) 2 (9.5) 1 (7.1) 0 (0.0)  
Male 18 (81.8) 19 (90.5) 13 (92.9) 6 (100.0) 
 
Age 2 44.3 (6.7) 40.1 (6.4) 44.1 (5.8) 42.3 (6.5) 0.163 
      
Duration of HIV 
infection years 2  
13.1 (6.2) 12.3 (5.0) 12.6 (5.8) 12.2 (4.1) 0.959 
CD4 cell count 3 444 (297-642) 367 (291-560) 327 (236-507) 346 (143-375) 0.344 
<50 HIV RNA 
copies/mL
 1 
19 (86.4) 20 (97.2) 12 (85.7) 5 (83.3) 0.887 
cART cumulative 
exposure years
 2 9.4 (4.7) 9.2 (4.9) 9.1 (5.2) 6.0 (4.4) 0.492 
ART 1 
     
PI  11 (50.0) 16 (76.2) 10 (78.6) 4 (66.7) 0.349 
NNRTI 12 (54.5) 6 (28.6) 3 (21.4) 0 (0) 0.040 
NRTI 20 (90.2) 19 (90.5) 12 (85.7) 6 (100.0) 0.933 
G      
Duration of HCV 
infection  years 2 
11.7 (5.8) 8.6 (4.1) 9.9 (4.5) 15.0 (2.4) 0.022 
HCV RNA log10 
3 6.3 (5.6-6.9) 5.8 (5.0-6.5) 6.2 (5.5-6.7) 5.7 (4.8-6.3) 0.410 
Genotype 1 
    
0,017 
       1 14 (63.6) 12 (57.1) 12 (85.7) 6 (100.0) 
 
       3 3 (13.6) 9 (42.9) 1 (7.1) 0 (0.0) 
 
       4 5 (22.5) 0 (0.0) 1 (7.1) 0 (0.0) 
 
 
sjgsh 
    
Alcohol consumption1 9 (40.9) 8 (38.1) 7 (50.0) 3 (50.0) 0.887 
1 – number (%); 2 – mean (SD); 3 – median (IQR) 
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Table 4  - Clinical and metabolic features of the HIV/HCV coinfected patients 
according to liver fibrosis stage. 
 
Without 
Significant 
Fibrosis 
Undetermined 
Fibrosis 
Significant 
Fibrosis 
Cirrhosis p 
      
BMI kg/m2 1 23.0 (3.5) 21.8 (2.4) 22.7 (3.4) 22.2 (1.6) 0.942 
Waist circumference  cm 1 85.6 (9.3) 85.3 (7.7) 87.7 (8.5) 79.0 (4.0) 0.215 
      
High blood pressure2  2 (9.1) 1 (4.8) 2 (14.3) 0 (0) 0.839 
Antihypertensive 
medication2  
1 (4.5) 0 (0) 0 (0) 0 (0) 1.000 
      
Total cholesterol mg/dL 1 179 (31) 173 (30) 157 (40) 131 (37) 0.015 
LDL cholesterol  mg/dL 1 103 (20) 102 (21) 91 (32) 74 (24) 0.057 
HDL cholesterol  mg/dL 1 50 (16) 45 (16) 47 (16) 37 (5) 0.299 
Non-HDL Cholesterol  
mg/dL 
1 
128 (25) 128 (30) 110 (34) 94 (37) 0.035 
Triglycerides mg/dL 1 155 (67) 157 (72) 121 (72) 135 (89) 0.458 
Antidyslipidemic 
therapy1 
4 (18.2) 4 (19.0) 2 (14.3) 0 (0) 0.915 
      
GOT U/L 3 37 (22-61) 37 (26-68) 48 (37-78) 82 (44-167) 0.036 
GPT  U/L 3 49 (17-75) 55 (37-107) 66 (44-109) 75 (28-148) 0.234 
GGT U/L 3 55 (32-164) 95 (48-180) 99 (72-116) 161 (44-180) 0.537 
ALP   U/L 3 94 (75-115) 92 (71-106) 89 (75-121) 108 (91-142) 0.498 
Total bilirubin  U/L 3 0.68 (0.53-0.90) 0.80 (0.53-1.37) 0.74 (0.46-1.15) 1.12 (0.73-1.78) 0.186 
Albumin g/L 1 43 (41-45) 44 (43-46) 42 (42-45) 41 (33-44) 0.005 
Platelets x109/L 1 184 (55) 181 (80) 156 (63) 137 (46) 0.314 
Prothrombin time  mg/dL 1 11.6 (1.0) 12.4 (1.6) 12.7 (1.5) 13.4 (1.0) 0.103 
Fibrinogen  mg/dL 1 348 (115) 380 (82) 288 (38) 313 (79) 0.310 
Dffg 
     
HOMA-IR 3 2.1 (1.5-2.9) 2.2 (1.0-4.2) 2.0 (0.9-3.4) 1.1 (0.7-2.8) 0.593 
HOMA-IR ≥ 2 2 12 (54.5) 11 (52.4) 7 (50.0) 2 (33.3) 0.876 
HOMA-IR ≧4 2 2 (9.1) 6 (28.6) 3 (21.4) 0 (0) 0.272 
QUICKI 3 0.34 (0.33-0.36) 0.34 (0.31-0.39) 0.34 (0.32-0.39) 0.38 (0.33-0.41) 0.593 
Glucose mg/dL 3 85.5 (81.8-95.0) 89.0 (79.5-92.0) 79.0 (73.0-86.8) 83.5 (75.8-101.3) 0.182 
Insulin  mU/L 3 9.9 (7.2-12.5) 13.1 (5.2-18.4) 9.4 (4.5-16.9) 6.2 (3.5-12.0) 0.511 
 
 
 
 
 
 
 
 
 
1 – mean (SD); 2 – number (%); 3 – median (min, max | IQR) 
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Table 5  - Correlations between metabolic characteristics and liver stiffness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Liver Stiffness 
 r p 
   
Total cholesterol mg/dL -0.427 <0.001 
LDL cholesterol  mg/dL -0.332 0.009 
HDL cholesterol  mg/dL -0.237 0.062 
Non-HDL Cholesterol  mg/dL -0.373 0.003 
Triglycerides mg/dL -0.144 0.261 
   
HOMA-IR 
 
-0.143 0.265 
QUICKI 
 
0.143 0.265 
Glucose mg/dL -0.302 0.016 
Insulin  U/L -0.092 0.471 
HbA1c  % 0.122 0.553 
   
GOT  U/L 0.338 0.007 
Albumin  g/L -0.643 <0.001 
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Table 6  - Association between clinical and metabolic characteristics and liver 
stiffness. 
 
 
 
 
 
 
 
 
 
 
* β coefficients adjusted for all the variables in the table. 
  
Liver stiffness 
 
 β* (95% CI) 
   
Age  years -0.144 (-0.336 to 0.048) 
NNRTI -2.298 (-4.887 to 0.292) 
Total cholesterol  mg/dL -0.038 (-0.074 to -0.001) 
TGO ln 2.111 (-0.101 to 4.324) 
Albumin  g/L -0.896 (-1.191 to -0.602) 
Glucose ln 
 
-0.110 (-8.327 to 8.107) 
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Endnotes
Endnotes should be designated within the text using a superscript lowercase letter and all notes (along with their corresponding letter) should be included in the
Endnotes section. Please format this section in a paragraph rather than a list.
References
All references, including URLs, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, followed by any in tables or
legends. Each reference must have an individual reference number. Please avoid excessive referencing. If automatic numbering systems are used, the reference
numbers must be finalized and the bibliography must be fully formatted before submission.
Only articles, datasets, clinical trial registration records and abstracts that have been published or are in press, or are available through public e-print/preprint servers,
may be cited; unpublished abstracts, unpublished data and personal communications should not be included in the reference list, but may be included in the text and
referred to as "unpublished observations" or "personal communications" giving the names of the involved researchers. Obtaining permission to quote personal
communications and unpublished data from the cited colleagues is the responsibility of the author. Footnotes are not allowed, but endnotes are permitted. Journal
abbreviations follow Index Medicus/MEDLINE. Citations in the reference list should include all named authors, up to the first 30 before adding 'et al.'..
Any in press articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial
office.
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Style files are available for use with popular bibliographic management software:
Examples of the BMC Infectious Diseases reference style are shown below. Please ensure that the reference style is followed precisely; if the references are not in the
correct style they may have to be retyped and carefully proofread.
All web links and URLs, including links to the authors' own websites, should be given a reference number and included in the reference list rather than within the text of
the manuscript. They should be provided in full, including both the title of the site and the URL, in the following format: The Mouse Tumor Biology Database
[http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or group of authors can clearly be associated with a web link, such as for weblogs, then they should be
included in the reference.
Examples of the BMC Infectious Diseases reference style
Article within a journal
Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat Genet 1996, 13:266-267.
Article within a journal supplement
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of ab initio three-dimensional prediction, secondary structure, and
contacts prediction. Proteins 1999, 43(Suppl 3):149-170.
In press article
Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in press.
Published abstract
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis [abstract].
Arthritis Rheum 1999, 42:s250.
Article within conference proceedings
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y.
Stoneham: Butterworth-Heinemann; 1996:16-27.
Book chapter, or article within a book
Schnepf E: From prey via endosymbiont to plastids: comparative studies in dinoflagellates. In Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin
RA. New York: Chapman and Hall; 1993:53-76.
Whole issue of journal
Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 1998, 10:1-72.
Whole conference proceedings
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996.
Complete book
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970.
Monograph or book in a series
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. Edited by Harris TJR. New York: Academic Press; 1995:54-56.
[Stoner G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.]
Book with institutional author
Advisory Committee on Genetic Modification: Annual Report. London; 1999.
PhD thesis
Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. Stanford University, Computer Science Department; 1995.
Link / URL
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]
Link / URL with author(s)
Corpas M: The Crowdfunding Genome Project: a personal genomics community with open source values
[http://blogs.biomedcentral.com/bmcblog/2012/07/16/the-crowdfunding-genome-project-a-personal-genomics-community-with-open-source-values/]
Dataset with persistent identifier
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, H-C (2011): Genome data from sweet and grain
sorghum (Sorghum bicolor). GigaScience. http://dx.doi.org/10.5524/100012.
Clinical trial registration record with persistent identifier
Mendelow, AD (2006): Surgical Trial in Lobar Intracerebral Haemorrhage. Current Controlled Trials. http://dx.doi.org/10.1186/ISRCTN22153967
Preparing illustrations and figures
Illustrations should be provided as separate files, not embedded in the text file. Each figure should include a single illustration and should fit on a single page in portrait
format. If a figure consists of separate parts, it is important that a single composite illustration file be submitted which contains all parts of the figure. There is no
charge for the use of color figures.
Please read our figure preparation guidelines for detailed instructions on maximising the quality of your figures.
Formats
The following file formats can be accepted:
PDF (preferred format for diagrams)
DOCX/DOC (single page only)
PPTX/PPT (single slide only)
EPS
BibTeX
EndNote style file
Reference Manager
Zotero
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PNG (preferred format for photos or images)
TIFF
JPEG
BMP
Figure legends
The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file. For each figure, the following
information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed
legend, up to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or tables that have
previously been published elsewhere.
Preparing tables
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title (above the table) that summarizes
the whole table; it should be no longer than 15 words. Detailed legends may then follow, but they should be concise. Tables should always be cited in text in
consecutive numerical order.
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 portrait or landscape format. These will be
typeset and displayed in the final published form of the article. Such tables should be formatted using the 'Table object' in a word processing program to ensure that
columns of data are kept aligned when the file is sent electronically for review; this will not always be the case if columns are generated by simply using tabs to
separate text. Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should not be used
to indicate numerical values. Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, the meaning of which should be
explained in a table legend. Tables should not be embedded as figures or spreadsheet files.
Larger datasets or tables too wide for a portrait page can be uploaded separately as additional files. Additional files will not be displayed in the final, laid-out PDF of the
article, but a link will be provided to the files as supplied by the author.
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma separated values (.csv). As with all files, please use the standard
file extensions.
Preparing additional files
Although BMC Infectious Diseases does not restrict the length and quantity of data included in an article, we encourage authors to provide datasets, tables, movies, or
other information as additional files.
Please note: All Additional files will be published along with the article. Do not include files such as patient consent forms, certificates of language editing, or revised
versions of the main manuscript document with tracked changes. Such files should be sent by email to editorial@biomedcentral.com, quoting the Manuscript ID
number.
Results that would otherwise be indicated as "data not shown" can and should be included as additional files. Since many weblinks and URLs rapidly become broken,
BMC Infectious Diseases requires that supporting data are included as additional files, or deposited in a recognized repository. Please do not link to data on a
personal/departmental website. The maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission.
Additional files can be in any format, and will be downloadable from the final published article as supplied by the author. We recommend CSV rather than PDF for
tabular data.
Certain supported files formats are recognized and can be displayed to the user in the browser. These include most movie formats (for users with the Quicktime
plugin), mini-websites prepared according to our guidelines, chemical structure files (MOL, PDB), geographic data files (KML).
If additional material is provided, please list the following information in a separate section of the manuscript text:
File name (e.g. Additional file 1)
File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL of an appropriate viewer if format is unusual)
Title of data
Description of data
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name within the body of the article, e.g. 'An additional movie
file shows this in more detail [see Additional file 1]'.
Additional file formats
Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely available tools. The following are examples of
suitable formats.
Additional documentation
PDF (Adode Acrobat)
Animations
SWF (Shockwave Flash)
Movies
MP4 (MPEG 4)
MOV (Quicktime)
Tabular data
XLS, XLSX (Excel Spreadsheet)
CSV (Comma separated values)
As with figure files, files should be given the standard file extensions.
Mini-websites
Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from within the full text HTML version of the article. In
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order to do this, please follow these instructions:
Create a folder containing a starting file called index.html (or index.htm) in the root.
Put all files necessary for viewing the mini-website within the folder, or sub-folders.
Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or "C:\Documents and
Settings\username\My Documents\mini-website\images\picture.jpg") and no link is longer than 255 characters.
Access the index.html file and browse around the mini-website, to ensure that the most commonly used browsers (Internet Explorer and Firefox) are able to
view all parts of the mini-website without problems, it is ideal to check this on a different machine.
Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the ZIP, and that the file has .zip extension, then
submit as an additional file with your article.
Style and language
General
Currently, BMC Infectious Diseases can only accept manuscripts written in English. Spelling should be US English or British English, but not a mixture.
There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise.
BMC Infectious Diseases will not edit submitted manuscripts for style or language; reviewers may advise rejection of a manuscript if it is compromised by grammatical
errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. In-house copyediting will be minimal. Non-
native speakers of English may choose to make use of a copyediting service.
Language editing
For authors who wish to have the language in their manuscript edited by a native-English speaker with scientific expertise, BioMed Central recommends Edanz. BioMed
Central has arranged a 10% discount to the fee charged to BioMed Central authors by Edanz. Use of an editing service is neither a requirement nor a guarantee of
acceptance for publication. Please contact Edanz directly to make arrangements for editing, and for pricing and payment details.
Help and advice on scientific writing
The abstract is one of the most important parts of a manuscript. For guidance, please visit our page on Writing titles and abstracts for scientific articles.
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. American Scientist also provides a list of resources for science writing. For
more detailed guidance on preparing a manuscript and writing in English, please visit the BioMed Central author academy.
Abbreviations
Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of abbreviations can be provided following the main
manuscript text.
Typography
Please use double line spacing.
Type the text unjustified, without hyphenating words at line breaks.
Use hard returns only to end headings and paragraphs, not to rearrange lines.
Capitalize only the first word, and proper nouns, in the title.
All lines and pages should be numbered. Authors are asked to ensure that line numbering is included in the main text file of their manuscript at the time of
submission to facilitate peer-review. Once a manuscript has been accepted, line numbering should be removed from the manuscript before publication. For
authors submitting their manuscript in Microsoft Word please do not insert page breaks in your manuscript to ensure page numbering is consistent between your
text file and the PDF generated from your submission and used in the review process.
Use the BMC Infectious Diseases .
Footnotes are not allowed, but endnotes are permitted.
Please do not format the text in multiple columns.
Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in
full. Please ensure that all special characters used are embedded in the text, otherwise they will be lost during conversion to PDF.
Units
SI units should be used throughout (liter and molar are permitted, however).
reference format

